search
Back to results

Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy

Primary Purpose

Pancreatic Ductal Adenocarcinoma, Surgery, Periampullary Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Total laparoscopic pancreaticoduodenectomy
Open pancreaticoduodenectomy
Sponsored by
Tongji Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Ductal Adenocarcinoma focused on measuring pancreaticoduodenectomy, surgical outcome

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically proven periampullary cancer, including pancreatic cancer, bile duct cancer, duodenal cancer, et al.
  2. Highly presumed malignancy with difficulties to obtain histological evidence.
  3. Preoperative staging work up performed by upper abdomen enhanced CT scan.
  4. The subject understands the nature of this trial and willing to comply.
  5. Ability to provide written informed consent.
  6. Patients treated with curative intent in accordance to international guidelines

Exclusion Criteria:

  1. Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, involvement of other organs.
  2. Subjects undergoing left, central or total pancreatectomy.
  3. Patients with high operative risk as defined by the American Society of Anesthesiologists (ASA) score >4.
  4. Synchronous malignancy in other organs.
  5. Previous underwent pancreatic resections.
  6. Palliative surgery.

Sites / Locations

  • Tongji HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

TLPD

OPD

Arm Description

Ttotal laparoscopic pancreaticoduodenectomy

Open pancreaticoduodenectomy

Outcomes

Primary Outcome Measures

Length of stay
Length of stay was defined as the postoperative time interval in days

Secondary Outcome Measures

Estimated blood loss
The amount of blood loss during surgical procedure.
Operation time
Time between first incision and last skin closure.
Mortality
Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.
Complication rate
Clavien-Dindo
CCI
comprehensive complication index
2 year survival
Overall survival rate for 24 months after surgery

Full Information

First Posted
February 7, 2017
Last Updated
October 5, 2020
Sponsor
Tongji Hospital
Collaborators
Shandong Provincial Hospital, The Second Hospital of Hebei Medical University, The Affiliated Hospital of Xuzhou Medical University, Xinqiao Hospital of Chongqing, Hunan Provincial People's Hospital, The First Hospital of Jilin University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The Third Affiliated Hospital of Soochow University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, First Affiliated Hospital of Chongqing Medical University, Peking Union Medical College Hospital, Henan Provincial People's Hospital, Sir Run Run Shaw Hospital, Fujian Medical University Union Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03138213
Brief Title
Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy
Official Title
Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy(TJDBPS01) a Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
May 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tongji Hospital
Collaborators
Shandong Provincial Hospital, The Second Hospital of Hebei Medical University, The Affiliated Hospital of Xuzhou Medical University, Xinqiao Hospital of Chongqing, Hunan Provincial People's Hospital, The First Hospital of Jilin University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The Third Affiliated Hospital of Soochow University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of North Sichuan Medical College, First Affiliated Hospital of Chongqing Medical University, Peking Union Medical College Hospital, Henan Provincial People's Hospital, Sir Run Run Shaw Hospital, Fujian Medical University Union Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Introduction Pancreatoduodenectomy (PD) is one of the most complex abdominal operations to perform, and it is usually conducted for tumours of the periampullary region and chronic pancreatitis. Minimally invasive surgery has been progressively being developed for pancreatic surgery, first with the advent of hybrid-laparoscopy and recently with total laparoscopic surgery. Issues including the safety and efficacy of total laparoscopic pancreaticoduodenectomy (TLPD) and open pancreaticoduodenectomy (OPD) are currently being debated. Studies comparing these two surgical techniques are emerging, and large randomized controlled trials (RCTs) are lacking but are clearly required. Methods and analysis TJDBPS01 is a multicentre, prospective, randomized controlled, parallel-group, superiority trial in fourteen centres with pancreatic surgery experts who have performed ≥104 TLPDs and OPDs. A total of 656 patients who will undergo PD are randomly allocated to the TLPD group or OPD group in a 1:1 ratio. The trial hypothesis is that TLPD has superior or equivalent safety and advantages in postoperative recovery compared with OPD. The primary outcome is the postoperative length of stay (LOS). Ethics and dissemination The Instituitional Review Board Approval of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology has approved this trial and will be routinely monitoring the trial at frequent intervals, as will an independent third-party organization. Any results from this trial (publications, conference presentations) will be published in peer-reviewed journals and conference proceedings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Ductal Adenocarcinoma, Surgery, Periampullary Cancer
Keywords
pancreaticoduodenectomy, surgical outcome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
656 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TLPD
Arm Type
Experimental
Arm Description
Ttotal laparoscopic pancreaticoduodenectomy
Arm Title
OPD
Arm Type
Experimental
Arm Description
Open pancreaticoduodenectomy
Intervention Type
Procedure
Intervention Name(s)
Total laparoscopic pancreaticoduodenectomy
Intervention Description
Total laparoscopic pancreaticoduodenectomy
Intervention Type
Procedure
Intervention Name(s)
Open pancreaticoduodenectomy
Intervention Description
Open pancreaticoduodenectomy
Primary Outcome Measure Information:
Title
Length of stay
Description
Length of stay was defined as the postoperative time interval in days
Time Frame
Up to 24 months
Secondary Outcome Measure Information:
Title
Estimated blood loss
Description
The amount of blood loss during surgical procedure.
Time Frame
Up to 24 months
Title
Operation time
Description
Time between first incision and last skin closure.
Time Frame
Up to 24 months
Title
Mortality
Description
Mortality was defined as any death that occurred in the 30 days after surgery or during the hospital stay.
Time Frame
Up to 24 months
Title
Complication rate
Description
Clavien-Dindo
Time Frame
Up to 24 months
Title
CCI
Description
comprehensive complication index
Time Frame
Up to 24 months
Title
2 year survival
Description
Overall survival rate for 24 months after surgery
Time Frame
Up to 24 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically proven periampullary cancer, including pancreatic cancer, bile duct cancer, duodenal cancer, et al. Highly presumed malignancy with difficulties to obtain histological evidence. Preoperative staging work up performed by upper abdomen enhanced CT scan. The subject understands the nature of this trial and willing to comply. Ability to provide written informed consent. Patients treated with curative intent in accordance to international guidelines Exclusion Criteria: Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, involvement of other organs. Subjects undergoing left, central or total pancreatectomy. Patients with high operative risk as defined by the American Society of Anesthesiologists (ASA) score >4. Synchronous malignancy in other organs. Previous underwent pancreatic resections. Palliative surgery.
Facility Information:
Facility Name
Tongji Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hang Zhang, M.D.
Phone
+8613407148260
Email
okashiiyo@126.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33915091
Citation
Wang M, Li D, Chen R, Huang X, Li J, Liu Y, Liu J, Cheng W, Chen X, Zhao W, Li J, Tan Z, Huang H, Li D, Zhu F, Qin T, Ma J, Yu G, Zhou B, Zheng S, Tang Y, Han W, Meng L, Ke J, Feng F, Chen B, Yin X, Chen W, Ma H, Xu J, Liu Y, Lin R, Dong Y, Yu Y, Liu J, Zhang H, Qin R; Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):438-447. doi: 10.1016/S2468-1253(21)00054-6. Epub 2021 Apr 27.
Results Reference
derived
PubMed Identifier
32047015
Citation
Zhang H, Feng Y, Zhao J, Chen R, Chen X, Yin X, Cheng W, Li D, Li J, Huang X, Li J, Liu J, Liu J, Liu Y, Tan Z, Zhao W, Huang H, Li D, Yu Y, Wang M, Qin R. Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01): study protocol for a multicentre, randomised controlled clinical trial. BMJ Open. 2020 Feb 10;10(2):e033490. doi: 10.1136/bmjopen-2019-033490.
Results Reference
derived

Learn more about this trial

Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy

We'll reach out to this number within 24 hrs